Brickell Biotech — Technical Presentation (April 2021)
19 slides from Brickell Biotech's technical presentation, Apr 23, 2021
Slide 1: ARGYLE: U.S. Phase 3 Open-Label, Long-Term Safety Study
© BrickellBio NASDAQ: BBI ARGYLE: U.S. Phase 3 Open- Label, Long-Term Safety Study r « Making Fresh Tracks in Dermatology® Investor Call | April 23, 2021
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements that involve substantial risk and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation other than statements of hi
Slide 3: Study authors and affiliations
Brandon M Kirsch, MD", Stacy Smith, MD2, Joel Cohen, MD3, Janet DuBois, MD4, Adelaide Hebert, MD5, Tory Sullivan, MD¢, Lawrence Green, MD’, Neal Bhatia, MD, David Pariser, MD?, Ping-Yu Liu, PhD'°, Deepak Chadha, MS, MBA, RAC"! 1Kirsch Dermatology, Naples, FL, 2California Dermatology and Clinical Res
Slide 4: Disclosures
Disclosures » Funding/Support The following clinical trial was supported by Brickell Biotech, Inc. > Financial Disclosures Stacy Smith, MD, Joel Cohen, MD, Janet DuBois, MD, Tory Sullivan, MD, Lawrence Green, MD, Neal Bhatia, MD, and David Pariser, MD were study investigators and received payment fr
Slide 5: Hyperhidrosis Background
Hyperhidrosis Background * Hyperhidrosis affects 4.8% of U.S. or >15M individuals! ¢ Over 10 million individuals in the U.S. suffer from axillary hyperhidrosis (AHH)! * 75% of HH sufferers report a profoundly negative impact on their social life, wellbeing, emotional and mental health! ¢ Long-term t
Slide 6: Topical Retrometabolic Anticholinergic Agent
Topical Retrometabolic Anticholinergic Agent MECHANISM OF ACTION * Sofpironium bromide is an analog of glycopyrrolate (an anticholinergic agent). It is an investigational drug in the United States, intended for the topical treatment of primary axillary hyperhidrosis. * Retrometabolic molecules are d
Slide 7: Study Objectives, Design and Methods
Study Objectives, Design and Methods In this open-label trial, the long-term safety, tolerability and efficacy of SB gel was evaluated in adult and pediatric subjects (300 total) with primary axillary hyperhidrosis* OBJECTIVES TREATMENT DURATION RANDOMIZATION KEY INCLUSION CRITERIA STUDY ASSESSMENTS
Slide 8: Subject Disposition
Subject Disposition A total of 190 subjects completed this long-term open-label safety study vat SSgRLR SEL SR Safety Population 299 102! 197 Early Terminations 110 31 (30.4) 79 (40.1) Due to Non-AEs 73 26 (25.5) 47 (23.9) Due to AEs 37 5 (4.9) 32 (16.2) Completed 52 Weeks (EOS) 190 72 (70.6) 118 (5
Slide 9: Safety Summary at Week 48 End of Treatment
Safety Summary at Week 48 End of Treatment SB gel safety results were consistent with a prior Phase 2b dose-finding study’ Majority of the AEs were mild or moderate in severity and transient in nature TEAE = Treatment-Emergent Adverse Event pas i peel te Any TEAE, n (%) 58 (56.9) 131 (66.5) Treatmen
Slide 10: Incidence of Treatment-Related TEAEs Occurring in ≥5% of Subjects
Incidence of Treatment-Related TEAEs Occurring in 25% of Subjects Long-term (48 weeks) daily topical application of sofpironium bromide gel was generally well tolerated 4 SB gel, 5% SB gel, 15% Preferred Term (N= 102) (N=197) Anticholinergic AEs Blurred Vision 4.9% 18.8% Dry Mouth 8.8% 16.8% Mydrias
Slide 11: Percentage of Subjects with Treatment-Related TEAEs Over Time
Percentage of Subjects with Treatment-Related TEAEs Over Time The incidence of subjects with any TEAEs tended to decrease over time as remaining subjects acclimated to treatment 20% mSB5% a m@SB 15% i 15% = 2 E ZF 10% _ a 6 ° = 3 5% 8 0% z 4 6 8 12 24 48 Subjects at Study Visit [1] Visit (Weeks) SB
Slide 12: Percentage of Subjects Discontinued Due to TEAEs Over Time
Percentage of Subjects Discontinued Due to TEAEs Over Time The incidence of discontinuations due to TEAEs tended to decrease over time as remaining subjects acclimated to treatment 10% mSB 5% B MSB 15% 2 8% € 8 ow 6% 28 te Bo 4% 34 ra 2 5 2% 8 5 2 0% Oto 6 Weeks >6 to 12 Weeks >12 to 24 Weeks >24 to
Slide 13: Summary of Anticholinergic AEs
Summary of Anticholinergic AEs For both concentrations, the observed anticholinergic adverse events were mostly mild or moderate in severity and transient in nature PREFERRED TERM each pecan ok All Anticholinergic 16 (15.7) 56 (28.4) Blurred Vision 5 (4.9)! 37 (18.8)2 Dry Mouth 9 (8.8) 33 (16.8) Myd
Slide 14: Discontinuation Due to Anticholinergic AEs
Discontinuation Due to Anticholinergic AEs There were few anticholinergic TEAEs leading to study discontinuation PREFERRED TERM poe a peony All Anticholinergic 3 (3.0) 16 (8.1) Blurred Vision’ 2 (2.0) 14 (7.1) Dry Mouth 0 1 (0.5) Mydriasis 0 1 (0.5) Urinary Retention 1 (1.0) 0 Dry Eye 0 0 ‘The sever
Slide 15: Percentage of Subjects Discontinued Due to Anticholinergic TEAEs Over Time
Percentage of Subjects Discontinued Due to Anticholinergic TEAEs Over Time The incidence of discontinuations due to anticholinergic TEAEs tended to decrease over time as remaining subjects acclimated to treatment 10% SB 5% g SB 15% fal 8% = 3 ee 25 € 6% ge ae 2 4% a2 BR Sz < a | : me a g & 0% Oto 6
Slide 16: Efficacy Assessment: HDSM-Ax Responder Analysis
Efficacy Assessment: HDSM-Ax Responder Analysis 1- and 2-point responders on the HDSM-Ax scale at end of treatment Week 48 suggests clinically meaningful improvement of sweat severity HDSM-Ax Responders (5% Group) HDSM-Ax Responders (15% Group) Week 48 (EOT) Week 48 (EOT) 100% g ime 86.1% g 85.8% B
Slide 17: Efficacy Assessment: HDSM-Ax Response Over Time
Efficacy Assessment: HDSM-Ax Response Over Time There appears to be efficacy over 48 weeks of treatment as measured by 22-point improvement in HDSM-Ax 10 mSB 5% End of Treatment (Wk. 48) WSB 15% I 08 2 I R 1 3 1 B 06 g 1 § ! g 04 I : 1 < 1 02 : 1 1 00 : IK 2 WK 4 WK 6 WK8 WK129 WK16 WK20) WK24 WK28
Slide 18: Conclusion
Conclusion Safety of long-term daily topical application of SB gel, 5% and 15% was consistent with prior clinical experience. Both concentrations led to measurable improvements in sweating severity for the majority of subjects » For both concentrations, observed TEAEs and anticholinergic adverse eve
Slide 19: Making Fresh Tracks in Dermatology
© BrickellBio NASDAQ: BBI r « Making Fresh Tracks in Dermatology® Investor Call | April 23, 2021
Brickell Biotech — Technical Presentation (April 2021) on 6ix